New multi-cancer early detection test from Knowledge on the Go

New multi-cancer early detection test

14 minutes Posted Sep 19, 2022 at 5:00 am.

] The Grail Galleri liquid biopsy test.

] Sampling methodology.

] The analytic process of the Grail Galleri test, and some developmental history.

] Testing methodology is based on methylation patterns.

] Results of the clinical studies to-date, and status of ongoing studies.

] Early adopters include some larger healthcare systems and, potentially, anyone willing to self-pay.

] Test costs and preliminary cost/benefit anaylsis.

] Considerations re: payers’ willingness to cover test costs.

] Looking forward to trial results and potential FDA approval.

] With many companies doing R&D in the liquid biospy field, the development of competing and complementary tests is to be expected.

0:00

14:53

Download MP3

Share at current time

Show notes

Early detection of cancer can dramatically increase the efficacy of curative treatment. Unfortunately, early screening tests exist for only a small number of cancers, meaning most are not diagnosed until symptoms arise in the later stages of the disease.

Better cancer screening is, therefore, a major focus area for clinical performance improvement. Marilyn Sherrill talks with Dr. Joe Cummings about a new genomic test that can theoretically screen for more than 50 different types of cancer using a small blood sample, and what the future may hold for this technology.

Guest speaker:

Joe Cummings, PhD

Technology Program Director

Vizient

Moderator:

Marilyn Sherrill, RN, MBA

Performance Improvement Program Director

Vizient

Show Notes:

[

Subscribe Today!

Apple Podcasts

Amazon Podcasts

Spotify

Google Podcasts

Android

Stitcher

RSS Feed

← See all 108 episodes of Knowledge on the Go